Our results provided evidence that synthetic IDH-mutant glioblastomas improved the visual diagnosis of tumors with IDH mutations and demonstrated the potential to improve noninvasive identification of IDH-mutant tumors, thus overcoming the small sample size inherent in imaging-based genomic and molecular prediction. This evidence concerns the gene IDH1 and glioblastoma.